Advanced Search

Decree No. 2011-1947 December 23, 2011 On The Publication Of The Amendment To The Annex Of The Convention Against Doping, Adopted On 7 November 2011 In Strasbourg And In Annex 1 Of The International Convention Against Doping In Sport, Has...

Original Language Title: Décret n° 2011-1947 du 23 décembre 2011 portant publication de l'amendement à l'annexe de la convention contre le dopage, adopté le 7 novembre 2011 à Strasbourg, et à l'annexe 1 de la convention internationale contre le dopage dans le sport, a...

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
Learn more about this text...

Information on this text

Summary

Implementation of articles 52 to 55 of the Constitution.

Keywords

AFFAIRS AND EUROPEAN , INTERNATIONAL AGREEMENT , MULTILATERAL AGREEMENT , UNESCO , INTERNATIONAL CONVENTION , SPORTS , SPORTIF , SUBSTANCE DOPANTE , STIMULANT , INTERDICTION , SPORTIVE COMPETITION , ANTIDOPAGE , LUTTE CONTROL


JORF n°0299 of 27 December 2011 page 22286
text No. 9



Decree No. 2011-1947 of 23 December 2011 on the publication of the amendment to the Annex to the Convention against Doping, adopted on 7 November 2011 in Strasbourg, and Appendix 1 of the International Convention against Doping in Sport, adopted on 14 November 2011 in Paris (1)

NOR: MAEJ1132732D ELI: https://www.legifrance.gouv.fr/eli/decret/2011/12/23/MAEJ1132732D/jo/texte
Alias: https://www.legifrance.gouv.fr/eli/decret/2011/12/23/2011-1947/jo/texte


President of the Republic,
On the report of the Prime Minister and the Minister of State, Minister for Foreign and European Affairs,
Considering the Constitution, in particular articles 52 to 55;
Vu le Decree No. 53-192 of 14 March 1953 amended on the ratification and publication of international commitments undertaken by France;
Vu le Decree No. 2007-503 of 2 April 2007 publishing the international convention against doping in sport (two annexes), adopted in Paris on 19 October 2005;
Vu le Decree No. 2008-35 of 10 January 2008 publishing the amendment to the annex to the Convention against Doping, adopted by the follow-up group at its 26th meeting on 12 November 2007 in Madrid;
Vu le Decree No. 2009-93 of 26 January 2009 having published the amendment to the annex to the convention against doping, adopted on 13 November 2008 in Strasbourg, and Appendix 1 of the international convention against doping in sport, adopted on 17 November 2008 in Paris;
Vu le Decree No. 2010-134 of 10 February 2010 publishing the amendment to the annex to the convention against doping, adopted on 18 November 2009 in Strasbourg, and Appendix 1 of the international convention against doping in sport, adopted in Paris on 28 October 2009;
Vu le Decree No. 2010-1578 of 16 December 2010 publishing the amendment to the annex to the convention against doping, adopted on 8 and 9 November 2009 in Strasbourg, and Appendix 1 of the international convention against doping in sport, adopted in Paris on 17 November 2010,
Decrete:

Article 1


The amendment to the appendix to the convention against doping, adopted on 7 November 2011 in Strasbourg, and to Annex 1 of the international convention against doping in sport, adopted on 14 November 2011 in Paris, will be published in the Official Journal of the French Republic.

Article 2


The Prime Minister and the Minister of State, Minister for Foreign and European Affairs, are responsible, each with regard to him, for the execution of this decree, which will be published in the Official Journal of the French Republic.



L I S T E
SUBSTANCES AND INTERNATIONAL METHODS
IN THE SPORT (LIST 2012)


Amendment to the Annex to the Convention against Doping, adopted on 7 November 2011 in Strasbourg, and to Annex 1 of the International Convention against Doping in Sport, adopted on 14 November 2011 in Paris


Global anti-doping code
LIST OF PROHIBITIONS 2012
STANDARD INTERNATIONAL
This list will come into force on January 1, 2012.
LIST OF PROHIBITIONS 2012
CODE MONDIAL ANTIDOPAGE
Effective January 1, 2012


In accordance with Article 4.2.2 of the World Anti-Doping Code, all prohibited substances must be considered as "specified substances" except substances in classes S1, S2, S4.4, S4.5, S6.a, and prohibited methods M1, M2 and M3.


SUBSTANCES AND INTERNATIONAL METHODS
EN PERMANENCE (EN ET HORS COMPÉTITION)
SUBSTANCES INTERDITES


S0. SUBSTANCES NON APPROVED
Any pharmacological substance not included in a section of the List below and which is not currently approved for therapeutic use in humans by a government health regulatory authority (e.g. preclinical or clinical development drugs or that are no longer available, drugs in a manner, veterinary drugs) is permanently prohibited.
S1. ANABOLISANT AGENTS
Anabolic agents are forbidden.
1. Androgenic anabolic steroids (SAA)
a. Exogenous SAA*, including:
1-androstènediol (5-androst-1-ène-3,17-diol) ; 1-androstènedione (5-androst-1-ène-3,17-dione) ; bolandiol (estr-4-ène-3,17-diol); bolasterone; boldenone; boldione (androsta-1,4-diène-3,17-dione); calusterone; enclosedbol; danazol (17-ethynyl-17-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17-hydroxy-17-methylandrosta-1,4-diène-3-one); deoxymethyltestosterone (17-methyl-5-androst-2-en-17-ol); drostanolone; ethylestrenol (19-nor-17-pregn-4-en-17-ol) ; fluoxymesterrone ; formationbolone ; ferazabol (17-hydroxy-17-methyl-5-androstano[2,3-c]-furazan) ; gestrinone ; 4-hydroxytestosterone (4,17-dihydroxyandrost-4-en-3-one) ; mestanolone ; mesterolone ; méténolone ; methanediénone (17-hydroxy-17-methylandrosta-1,4-diène-3-one); methandriol; methasterone (2, 17-dimethyl-5-androstane-3-one-17-ol); methyldiénolon (17-hydroxy-17-methylestra-4,9-diène-3-one) ; methyl-1-testosterone (17-hydroxy-17-methyl-5-androst-1-en-3-one) methylnortestosterone (17-hydroxy-17-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltriènolone, 17-hydroxy-17-methylestra-4,9,11-triène-3-one); mibolone; nandrolone; 19-norandrostendione (estr-4-ene-3,17-dione); norboletone; norclostebol; Norethandrolone ; oxabolone ; oxandrolone ; oximesterrone; oxymetholone; prostanozol (17-hydroxy-5-androstano[3,2-c]pyrazole) ; quinbolone ; stanozolol ; stenbolone ; 1-testosterone (17-hydroxy-5-androst-1-ène-3-one) ; tetrahydrogestrinone (18a-homo-pregna-4,9,11-trine-17-ol-3-one); trenbolone; and other substances having a similar chemical structure or a similar biological effect(s).
b. Endogenous SAA** by exogenous administration:
androstènediol (androst-5-ène-3,17-diol) ; androstènedione (androst-4-ène-3,17-dione) ; dihydrotestosterone (17-hydroxy-5-androstan-3-one) ; prasterone (dehydroepandrosterone, DHEA) ; testosterone and the following metabolites and isomers, including but not limited to:
5-androstane-3,17-diol; 5-androstane-3,17-diol; 5-androstane-3,17-diol; 5-androstane-3,17-diol; androst-4-ene-3,17-diol; androst-4-ene-3,17-diol; androst-4-ene-3,17-diol; androst-5-ene-3,17-diol; androst-5-ene-3,17-diol; androst-5-ene-3,17-diol; 4-androstènediol (androst-4-ène-3,17-diol) ; 5-androstènedione (androst-5-ène-3,17-dione) ; epidihydrotestosterone ; epitestosterone ; 3-hydroxy-5-androstan-17-one; 3-hydroxy-5-androstan-17-one; 7-hydroxy-DHEA; 7-hydroxy-DHEA; 7-keto-DHEA; 19-norandrosterone; 19-norétiocholanolone.
2. Other anabolic agents, including but not limited to:
Clenbuterol, selective modulators of androgenic receptors (SARMs), tibolone, zéranol, zilpatrol.
For the purposes of this document:
* "exogenous" means a substance that cannot usually be produced naturally by the human body.
** "endogenous" means a substance that can be produced naturally by the human body.
S2. PEPTIDICAL HORMONS, CROISSANCE FACTORS AND APPROVAL SUBSTANCES
The following substances and their release factors are prohibited:
1. Erythropoiesis stimulant agents [e.g. erythropoietin (EPO), darbepoetin (DEPO), methoxy polyethylene glycol-epoetin beta (CERA), petginesatide (Hematide), stabilizing factors inductible by hypoxia (HIF));
2. chorionic Gonadotrophin (CG) and luteinizing hormone (LH), prohibited in male sports only;
3. Insulins;
4. Corticotrophines;
5. Growth Hormone (GH), growth factor similar to insulin-1 (IGF-1), growth factor derived from platelets (PDGF), endothelial vascular growth factor (VEGF), hepatocyte growth factor (HGF), fibroblastic growth factors (FGF), mechanical growth factors (MGF), as well as any other growth factor influencing
and other substances having a similar chemical structure or a similar biological effect(s).
S3. BÊTA-2 AGONISTS
All beta-2 agonists (including their two optical isomers if applicable) are prohibited, except salbutamol (maximum 1,600 micrograms per 24 hours), formoterol (maximum 36 micrograms per 24 hours) and salmeterol administered by inhalation in accordance with the therapeutic administration scheme recommended by the manufacturer.
The presence in the urine of salbutamol at a concentration greater than 1000 ng/mL or formoterol at a concentration greater than 30 ng/mL will be presumed not to be an intentional therapeutic use and will be considered as a result of abnormal analysis, unless the athlete proves by a controlled pharmacokinetic study that this abnormal result is the consequence of the use of a maximum dose by inhalation.
S4. HORMONAL AND METHODS
The following substances are prohibited:
1. Aromatase inhibitors, including but not limited to: aminoglutethhimide, anastrozole, androsta-1,4,6-trine-3,17-dione (androstatrenedione), 4-androstène-3,6,17 trione (6-oxo), exemestane, formstane, letrozole, testolactone.
2. Selective modulators of receptors to estrogen (SERM), including without limitation: raloxifen, tamoxifen, toremifen.
3. Other anti-estrogogenic substances, including but not limited to: clomifene, cyclofenil, fulvestrant.
4. Modifying agents of myostatin function(s), including without limitation: myostatin inhibitors.
5. Metabolic modulators: the receptor agonists activated by the proliferators of the peroxysomes (PPAR) (e.g. GW 1516) and the agonists of the PPAR-protein kinase axis activated by the AMPK (e.g. AICAR).
S5. DIURETIC AND OTHER MASQUANTS
Agents are forbidden. They include:
Diuretics, desmopressin, probenecide, plasma substitutes (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl stardon and mannitol), and other substances with similar biological effect(s).
The local application of felypressin in dental anesthesia is not prohibited.
Diuretics include:
Acetazolamide, amiloride, bumetanide, canrenone, chlortalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamten, and other substances with a similar chemical structure or
The use in competition, and out of competition if applicable, of any quantity of a substance being subject to a threshold level (i.e. formoterol, salbutamol, morphine, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the issuance of a diuretic authorization obtained for specific therapeutic purposes for that substance.


METHODS


M1. AMÉLIORATION DU TRANSFERT D'OXYGÈNE
The following is prohibited:
1. Blood doping, including the use of autologous blood products, counterparts or heterologists, or red blood cells of any origin.
2. Artificial improvement in the consumption, transport or release of oxygen, including, but not limited to, perfluorinated chemicals, efaproxiral (RSR13) and modified hemoglobin products (e.g. blood substitutes based on hemoglobin, reticulated hemoglobin products), but excluding oxygen supplementation.
M2. CHEMICAL AND PHYSICAL MANIPULATION
The following is prohibited:
1. Falsification, or attempted falsification, with the aim of altering the integrity and validity of samples collected during doping control, is prohibited. This category includes, but is not limited to, the substitution and/or alteration of urine (e.g. proteases).
2. Intravenous infusions and/or injections of more than 50 mL per 6-hour period are prohibited, except those legitimately received in hospital admissions or in clinical examinations.
3. The successive removal, handling and reintroducing any total blood volume in the circulatory system is prohibited.
M3. GENERAL DOPAGE
The following, having the potential capacity to improve sports performance, is prohibited:
1. Transfer of nucleic acids or nucleic acid sequences;
2. Use of normal or genetically modified cells.


SUBSTANCES AND METHODS
IN COMPETITION
In addition to the categories S0 to S5 and M1 to M3 defined above,
the following categories are prohibited in competition:
SUBSTANCES INTERDITES


S6. STIMULANTS
All stimulants (including their two optical isomers if applicable) are prohibited, with the exception of derivatives of imidazole under topical application and stimulants in the 2012 Monitoring Program*.
Stimulants include:
a: Stimulants not specified:
Adrafinil, amphetamine, mephenamine, phenamine A stimulant that is not specifically named in this section is a specified substance.
b: Specified stimulants (examples):
Adrenaline**, cathine***, ephedrine****, etamivan, etiléfrine, fenbutrazate, fencamfamine, heptaminol, isometalamine, levmetamfenoxate, methylethaneamine (dimethylpentylamine)
* Substances in the 2012 Surveillance Program (bupropion, caffeine, nicotine, phenylpropanolamine, pipradrol, synephrine) are not considered prohibited substances.
** Local use (e.g. nasal or ophthalmological path) of adrenaline or co-administration with local anesthetics are not prohibited.
*** Cathine is prohibited when its concentration in the urine exceeds 5 micrograms per millilitre.
**** Ephedrine and methylephedrine are prohibited when their respective concentrations in urine exceed 10 micrograms per millilitre.
***** The pseudoephedrine is prohibited when its concentration in the urine exceeds 150 micrograms per millilitre.
S7. NARCOTIQUES
The following is prohibited:
Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocin, penthidine.
S8. CANNABINOÏDES
Natural 9-tetrahydrocannabinol (THC) (e.g. cannabis, haschisch, marijuana) or synthetic and cannabimimetic (e.g. "Spice" [containing JWH018, JWH073], HU-210) are prohibited.
S9. GLUCOCORTICOÏDES
All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal.


SUBSTANCES IN SPORTS


P1. ALCOOL
Alcohol (ethanol) is prohibited in competition only in the following sports. The detection will be performed by ethylometry and/or blood analysis. The violation threshold (hematological values) is 0.10 g/L.
Aeronautics (FAI).
Automobile (FIA).
Karate (WKF).
Motorcycling (FIM).
Motonautique (UIM).
Archery (FITA).
P2. BÊTA-BLOQUANTS
Unless otherwise stated, beta-blockers are prohibited in competition only in the following sports:
Aeronautics (FAI).
Automobile (FIA).
Leg (all disciplines) (WCBS).
Balls (CMSB).
Bridge (FMB).
Darts (WDF).
Golf (IGF).
Motonautique (UIM).
Quilles (Neuf-et Dix-) (FIQ).
Ski (FIS) for ski jump, freestyle/halfpipe jump and halfpipe/big air snowboard.
Shooting (ISSF, IPC) (also banned out of competition).
Archery (FITA) (also banned out of competition).
Beta-blockers include but are not limited to:
Acebutolol, alprenolol, aténolol, betaxolol, bisoprolol, bunolol, cartéolol, carvedilol, celiprolol, esmolol, labétalol, lévobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, proptalranolol, so


Done on 23 December 2011.


Nicolas Sarkozy


By the President of the Republic:


The Prime Minister,

François Fillon

The Minister of State,

Minister for Foreign Affairs

and European,

Alain Juppé

(1) This amendment shall enter into force on 1 January 2012.
Download the document in RTF (weight < 1MB) Extrait du Journal officiel électronique authentifié (format: pdf, weight : 0.33 Mo) Download the document in RDF (format: rdf, weight < 1 MB)